Schnemann H, Broek J, Guyatt G, Oxman A. Furthermore, the studies demonstrating equivalent efficacy for fidaxomicin and vancomycin in initial clinical response to therapy for CDI generally excluded patients with fulminant disease. Any action by any such administrator within the scope of its delegation shall be deemed for all purposes to have been taken by the Committee and, except as otherwise specifically provided, references in this Plan to the Committee shall include any such administrator. AMCOR PLC CDI Simple Moving Average . Indeed, this study provided the rationale for the extended-pulsed fidaxomicin regimen that was used by Guery et al [18]. In the event of any stock dividend or split, recapitalization, merger, consolidation, combination or exchange of Shares, spin-off or similar corporate change or extraordinary cash dividend, the maximum aggregate number of Shares with respect to which the Committee may grant Incentive Awards, the number of Shares subject to Incentive Awards, the exercise price of any Option or base price of any share appreciation right and the applicable performance targets or criteria shall be equitably adjusted or substituted by the Committee to prevent enlargement or reduction in rights granted under the Incentive Award. oversee the issuance of Shares under Incentive Awards, to interpret and administer the terms of Incentive Awards, and to take such other actions as may be necessary or appropriate for the administration of the Plan and of Incentive Awards under the Plan, provided that in no case shall any such administrator be authorized (i)to take any action inconsistent with Section409A of the Code with respect to any Incentive Award subject to such provision or (ii)to take any action inconsistent with applicable law. About 35,000 of those shareholders hold fewer than 1000 Amcor shares, while 34,000 own between 1000 and 5000 Amcor shares. "Establishing the safety and efficacy associated with FMT in this patient population and others via randomized clinical trials will be an important development." Available at: Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Login . In order to manage these challenges, Amcor has in place a formal Tax Risk Management Framework. Lam SW, Neuner EA, Fraser TG, Delgado D, Chalfin DB. "RiskFactors"of Amcor'sannual report on Form 10-K for the fiscal year ended June 30, 2020. . Amcor has a large tail of retail investors among its 78,000 shareholders. I. These results are highly influenced by the assumptions made and data input in the model. JAMA Clinical Guidelines Synopsis: Diagnosis and treatment of Clostridium difficile infection. Another study comparing fidaxomicin and vancomycin use as initial therapy for CDI in the general population reported similar total treatment costs of $14 442 for fidaxomicin and $14 179 for vancomycin [25]. "My question to the Amcor chief executive is 'how committed are you to maintain the Amcor CDIs or are you going to review it like others have done a couple of years later?'. "These two medications have demonstrated superior efficacy and reduced rates of adverse events when compared with metronidazole. Changes to your shareholder details, such as a change of name or address, or notification of your tax file number or direct credit of dividend advice can be made by printing out the relevant forms, filling them in and sending the changes to Amcor's Share Registry. In addition, if Shares are issued subject to conditions which may result in the forfeiture, cancellation or return of such Shares to the Company, any portion of the Shares forfeited, cancelled or returned shall be treated as not issued pursuant to the Plan. Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine. 5. Definitions. Louie TJ, Cannon K, Byrne B, et al. Investors can use this forecasting interface to forecast AMCOR PLC historical stock prices and determine the direction of AMCOR PLC CDI's future trends based on various well-known forecasting models. V. L. has received past research funding from the Fonds de Recherche du Qubec Research (FRQ-S). This finding further supports the subanalyses of the bezlotoxumab phase III trials demonstrating that the choice of SOC antibiotics did not influence the effect of bezlotoxumab on clinical outcomes, but the combined effect of bezlotoxumab to fidaxomicin will need to be studied further. For example, patients who received metronidazole as a first line treatment should receive vancomycin or fidaxomicin for recurrences. (i) Except as to any Incentive Awards subject to Section409A of the Code, termination of Service shall mean a separation from service within the meaning of Section409A of the Code, unless the Participant is retained pursuant to a written agreement and such agreement provides otherwise. However, there was no heterogeneity (I2: 0%) between these subgroups and the pooled effect for patients with a recurrent CDI within the last 6 months was 17.4% (95% CI: 27.5% to 7.3%) (seeFigure 5). The tax credit amount that can be claimed depends on the amount of foreign tax due and U.S. tax liability. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). Madoff SE, Urquiaga M, Alonso CD, Kelly CP. "If Iron Mountain gets away with it scot-free, and welshes on one of their key terms, it sets a precedent for others to follow and that is not in Australian investors' interests," he said. Cornely OA, Watt M, McCrea C, Goldenberg SD, De Nigris E. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged 60 years (EXTEND): analysis of cost-effectiveness. (i) Committee means the Compensation Committee of the Board of Directors or such other committee as the Board of Directors shall appoint from time to time to administer the Plan and to otherwise exercise and perform the authority and functions assigned to the Committee under the terms of the Plan. The panel included physicians and pharmacists with expertise in infectious diseases, gastroenterology, pharmacy, medical microbiology, and epidemiology. In patients with recurrent CDI episodes, we suggest fidaxomicin (standard or extended-pulsed regimen) rather than a standard course of vancomycin (conditional recommendation, low certainty evidence). Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection. Nevertheless, a post hoc analysis showed that patients with a history of congestive heart failure (CHF) who received bezlotoxumab may be at increased risk of heart failure and mortality in the 12 weeks following the infusion (RR: 2.64 [95% CI: 1.007.03] and 1.56 [95% CI: .832.92], respectively) [40]. INTRODUCTION. (b) Cash-Based Awards. Chilton CH, Crowther GS, Todhunter SL, et al. Either drug was preferred over metronidazole, and this was a strong recommendation. Governing Law. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. All rights reserved. 2017;92:1617. Recent additional studies have been identified that also support its use in recurrent CDI. Get the latest Amcor CDI (AMCCF) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (iii)An Option shall be exercised by such methods and procedures as the Committee determines from time to time, including without limitation through net physical settlement or other method of cashless exercise. Amcor shareholder might subsequently make from their replacement New Amcor share or CDI would be disregarded, except because of a roll-over (paragraph 124-795(2)(a)). 2013. The panel agrees that the cost-effectiveness analysis favors the addition of bezlotoxumab to SOC antibiotics in patients with a recurrent CDI episode within the last 6 months but acknowledges that implementing this recommendation also probably reduces equity due to variation in medical insurance coverage. (h) Code means the Internal Revenue Code of 1986, as amended from time to time, and all regulations, interpretations and administrative guidance issued thereunder. the number and kind of shares and prices, (y)Incentive Awards may be terminated in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Incentive Award or realization of the Participants rights as of the date of occurrence of the Change in Control (and, for the avoidance of doubt, if as of the date of the occurrence of the Change in Control the Committee determines in good faith that no amount would have been attained upon the exercise of such Incentive Award or realization of the Participants rights, then such Incentive Award may be terminated by the Company without payment) or (z)outstanding Incentive Awards will terminate upon or immediately prior to the consummation of such Change in Control (provided that the Committee provides at least twenty days notice to the Participants holding such Incentive Awards and each Participant has had the right to exercise such Incentive Awards in full). It is important to realize that guidelines cannot always account for individual variation among patients. Gerding DN. Amcor shall inform the Participant in writing of its decision to defer the effectiveness of the exercise or settlement of an Incentive Award granted hereunder. Introduction to GRADE handbook. None of Amcor, New Amcor or Bemis, or any of their respective directors, executive officers or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur. AMCOR PLC CDI Accumulation Distribution . J Clin Gastroenterol 2016; 50:6317. The panel suggests the use of fidaxomicin as the preferred therapy for an initial CDI episode to improve sustained response after therapy but recognizes that vancomycin remains an acceptable alternative if fidaxomicin is not available. Except as expressly provided in the Plan, no issuance by Amcor of Shares of any class, or securities convertible into Shares of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares or amount of other property subject to, or the terms related to, any Incentive Award. A subgroup of panelists (K. W. G., A. J. G.-L., S. J., A. M. S.) screened titles and abstracts of all identified citations. Where applicable, the guideline methodologist pooled the data using a random-effects model (fixed-effects model for pooling of rates) using RevMan 5.4 [9]. What does Amcor mean? Cost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infection. Notwithstanding the foregoing, no Option shall be exercisable after the expiration of ten years from the date such Option is granted; provided, however that the expiration of the Option may be tolled while the Participant cannot exercise such Option because an exercise would violate an applicable law, or would jeopardize the ability of Amcor to continue as a going concern, provided, further that the period during which the Option may be exercised is not extended more than 30 days after the exercise of the Option first would no longer violate such applicable laws or jeopardize the ability of Amcor to continue as a going concern. While IDSA and SHEA make every effort to present accurate, complete, and reliable information, these guidelines are presented as is without any warranty, either express or implied. When treating patients for a second or subsequent recurrence, the guideline recommends pulse-tapered vancomycin or vancomycin for 10 days followed by rifaximin or fidaxomicin. Like vancomycin, it is orally delivered with minimal systemic absorption and it is highly active againstC. difficilein vitro. Bezlotoxumab, a monoclonal antibody against toxin B was recently approved by the Food and Drug Administration for treatment of CDI in patients at high risk of recurrence, based on results of two randomized, double-blind, placebo-controlled trials in 1,554 adults. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. AMCOR PLC. The results of the literature search were supervised and thoroughly reviewed by the guideline methodologist for the final selection of the relevant articles. Achieving both initial and sustained clinical responses are key goals of CDI therapy. Clin Infect Dis 2012; 55(Suppl 2):S1438. "Our view is they are agnostic about this," he said. 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. In addition, the financial affairs of multinational companies are complex. The FDA warns that in patients with a history of congestive heart failure (CHF), bezlotoxumab should be reserved for use when the benefit outweighs the risk.. The target audience for these guidelines includes general physicians, infectious diseases specialists, gastroenterologists, pharmacists, and other healthcare providers managing this condition. During this time period, the IDSA-SHEA 2010 Clinical Practice Guidelines for CDI suggested that metronidazole be used for mildmoderate CDI and oral vancomycin be given for more severe disease [39]. Amcor and Bemis combination Unanimously recommended by the Boards of Directors of both companies Amcor shareholders will receive one New Amcor CDI or share for each existing share held New Amcor to be NYSE and ASX listed Amcor and Bemis shareholders expected to own approximately 71% and 29% respectively Whenever withholding tax obligations are incurred in connection with any Incentive Award, Amcor shall have the right to require the Participant to either: (a)remit to Amcor in cash or (b)allow Amcor to withhold Share Incentive Awards with value equal to the amount of such withholding or (c)deduct an appropriate amount from other employment income payable by Amcor either immediately or over time. been deferred, the Participant may, by written notice, withdraw such exercise and obtain the refund of any amount paid with respect thereto. The Committee may delegate the administration of the Plan to one or more officers or employees of the Company, and such administrator(s)may have the authority to execute and distribute Award Agreements, to maintain records relating to Incentive Awards, to process or. Shares covered by Incentive Awards granted pursuant to the Plan in connection with the assumption, replacement, conversion or adjustment of outstanding equity-based awards in the context of a corporate acquisition or merger (within the meaning of Section303A.08 of the New York Stock Exchange Listed Company Manual) shall not count as used under the Plan for purposes of this Section3. (b) Term and Exercise of Options. For example, a study based on data from the registration trials [14,15] used a willingness to pay threshold of $50 000 per quality-adjusted life-year (QALY) gained and found that fidaxomicin had incremental cost-effectiveness ratios ranging from 26 900 (~US dollars [USD] 32 000) to 44 500 (~USD 52 000) per QALY gained versus vancomycin [24]. If an Amcor shareholder chooses scrip for scrip roll-over, the . Aug 10, 2018 - 10.45am Analysis of AMCOR PLC Simple Moving Average, A two period moving average forecast for AMCOR PLC is based on an daily price series in which the stock price on a given. BMJ 2008; 336:9246. Final presentation of evidence summaries and the development of the recommendations was performed by 2 conference calls with the whole expert panel on 22 and 26 June 2020. However, solely looking at the historical price movement is usually misleading. Available at: GRADEpro GDT. Rights Under the Plan, No Person shall have any rights as a shareholder with respect to any Shares covered by or relating to any Incentive Award until the date of the issuance of such Shares on the books and records of Amcor. Hefazi M, et al. Clin Infect Dis 2017; 65:13969. Resource use (monetary costs and cost-effectiveness, for example) was rated as of limited importance by the panel and was not included in the initial assessment. J Infect Chemother 2018; 24:74452. Version 5.4. Recoupment. Trends in U.S. burden of Clostridioides. PLoS One 2016; 11:e0149521. AMCOR PLC CDI 1:1. 2018;66:e1. Clin Infect Dis 2016; 62:57480. The risk difference for patients with primary CDI and with at least 1 risk factor who received bezlotoxumab was 15.1% (95% CI: 22.0% to 8.1%) and 1.5% (95% CI: 10.7% to 7.7%) for primary CDI patients without any risk factor (seeFigure 4). These recommendations were also labeled as weak due to the lack of high-quality evidence. Amcor Limited (ASX: AMC) is a global packaging company. Try Premium Dividend Yield Today 5.0% The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price Free Email Notification Amcor may, in its sole discretion, defer the effectiveness of any exercise or settlement of an Incentive Award granted hereunder in order to allow the issuance of Shares pursuant thereto to be made pursuant to registration or an exemption from registration or other methods for compliance available under federal or state or local securities laws. No part of these guidelines may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of IDSA. The updated guideline emphasized that antibiotic treatments should be administered for at least two recurrences before administering FMT. Shares issued under the Plan may be either authorized and unissued shares, treasury shares, shares purchased by the Company in the open market, or any combination of the preceding categories as the Committee determines in its sole discretion. As noted above, there is robust evidence supporting fidaxomicin treatment for patients with an initial episode of CDI. US Food and Drug Administration. The new recommendation is to treat adults with a nonfulminant initial CDI episode with vancomycin (125 mg given four times daily for 10 days) or fidaxomicin (200 mg given twice daily for 10 days) and limit the use of metronidazole to cases in which vancomycin or fidaxomicin are unavailable or contraindicated. A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text. For patients with a recurrent CDI episode within the last 6 months, we suggest using bezlotoxumab as a co-intervention along with SOC antibiotics rather than SOC antibiotics alone (conditional recommendation, very low certainty of evidence). You should take individual advice on the tax treatment of the dividend. (n) Eligible Person has the meaning set forth in Section5 of the Plan. The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. Patient-important outcomes were all reported in the study published by Wilcox et al [18], except for CDI-associated hospital readmission, which was only reported in a subgroup analysis of patients hospitalized at the time of randomization [18,19] (seeFigure 3). Two alerts document transmission of pathogenicEscherichia colifrom donor to FMT recipients, some of whom became ill and some of whom died [35]. Purpose of the Plan. Fulminant CDI is not common. Supplementary materials are available atClinical Infectious Diseases online. In settings where logistics is not an issue, patients with a primary CDI episode and other risk factors for CDI recurrence (such as age 65 years, immunocompromised host [per history or use of immunosuppressive therapy], and severe CDI on presentation) may particularly benefit from receiving bezlotoxumab. Wilcox MH, Gerding DN, Poxton IR, et al; MODIFY I and MODIFY II Investigators. With the addition of a new RCT comparing fidaxomicin and vancomycin, which also included patients with recurrent CDI [16], evidence now suggests fidaxomicin should be preferred over vancomycin in this setting. The 2017 guideline included 2 noninferiority RCTs evaluating the efficacy of fidaxomicin compared with vancomycin in patients with confirmed CDI on sustained response, on initial clinical cure, on drug-related adverse events, and on all-cause mortality [14,15]. A history of prior CDI is a prominent risk factor for further recurrences and is addressed separately below. In this article, gastroenterologists from Mayo Clinic's campuses in Florida, Arizona and Minnesota answer questions about first line antibiotic therapy and treatment of recurrent CDI. 12. Upon completing its $9 billion acquisition of US company Bemis, which was officially launched on Tuesday, Amcor's primary listing will shift to the New York Stock Exchange, leaving shareholders who want to continue owning the company within Australia with little choice but to hold CDIs. I. Decline in volumes, higher costs and supply-chain issues are hurting Amcor's (AMCR) price performance. Subpopulations that were shown to be most cost-effective, especially if the subgroups had 1 or more episodes of CDI in the previous 6 months, were immunocompromised patients, patients aged 65 years or older, and patients with severe CDI on presentation. 8. The observed lower recurrence rates following fidaxomicin therapy as compared with vancomycin are an important advantage. The rate of recurrent CDI at 90 days was 15.9% (31 of 195 patients), which did not differ when stratifying by SOC antibiotics received (vancomycin fixed dose in 10 out of 73 patients [13.7%], vancomycin tapered regimen in 11 out of 60 patients [18.3%], fidaxomicin in 9 out of 59 patients [15.2%];P=.76). Mr Illingworth runs boutique Melbourne outfit Kingfisher Capital, which serves as an investment office for several families, and he was left frustrated and "gobsmacked" in July when Iron Mountain announced it would cull its Australian CDI barely two years after declaring the retention of a local security was a "key transaction term" of the Recall acquisition. The panels expert experience also suggests that patients with multiple recurrent CDI episodes become increasingly desperate with each subsequent CDI episode and are willing to consider nonstandard or nonapproved therapies. "A bargain is a bargain, it is either solid or it is not, and in securities markets when you say something is a key term and you promise to do things, you should be good for your promises," he said. Head-to-head trials of differing anti-CDI recurrence strategies using narrow-spectrum antibiotics that targetC. difficile, restoration of the microbiome using biotherapeutics or FMT, or augmentation of the host immune response with agents such as bezlotoxumab given alone or in combination (eg, in combination with fidaxomicin) are needed. The purpose of this guideline is to provide evidence-based guidance on the most effective management of CDI and recurrent CDI in adult patients. However, based on decreasing efficacy of metronidazole, SOC antibiotics now include vancomycin and fidaxomicin in the updated 2017 IDSA-SHEA CDI guidelines [1]. The other alert concerns the potential for transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [6]. Guery B, Menichetti F, Anttila VJ, et al; EXTEND Clinical Study Group. All studies reported a similar rate of patients presenting with an initial episode of CDI (ranging from 79% to 86%) and with a comparable clinical severity on presentation (although definitions of severity differed between studies); the latter 2 studies restricted inclusion only to inpatients, in contrast with earlier studies where only 59% to 68% were hospitalized. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. These studies must also consider the nonfinancial benefits of reducing CDI recurrences. ZURICH, Feb. 7, 2023 /PRNewswire/ -- Amcor CEO Ron Delia said: "Amcor . Except for the permission granted above, any person or entity desiring to use the guidelines in any way must contact IDSA for approval in accordance with the terms and conditions of third-party usein particular, any use of the guidelines in any software product. This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. Definition of Amcor in the Definitions.net dictionary. Patients with primary CDI and no risk factors likewise did not benefit from bezlotoxumab. While additional data have been published for other treatment entities, the quality of the data was determined not sufficient to alter our current treatment recommendations. Get the latest Amcor PLC (AMCR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. In patients who received vancomycin initially, the guideline suggests the use of tapered-pulse vancomycin or fidaxomicin for recurrences. M. H. W. serves as an advisor for Summit and Seres; has served as an advisor for Merck and Astellas; receives research grants from Summit, Seres, the Centers for Disease Control and Prevention, the NIH, the UK Medical Research Council, and the European Union Innovative Medicines Initiative; and has received research grants from Merck and Astellas. "The low rate of adverse events and lack of infectious complications in this series prompted us to conclude that the presence of active malignancy or recent chemotherapy should not preclude the use of FMT in this high-risk population," explains Sahil Khanna, M.B.B.S. Help using this website - Accessibility statement. 2020. CDI represented a primary episode for 73% of participants and severe CDI accounted for 16% of cases; however, the assessment of severity was performed at the point of randomization to the study drug rather than when SOC antibiotic treatment was initiated. Consequently, the panel judges that patients experiencing recurrent CDI will invariably put a high value on avoidance of a subsequent CDI episode. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. (i) Each Option shall become vested and exercisable on such date or dates, during such period and for such number of Shares as set forth in the Award Agreement; provided that each Option shall be subject to earlier termination, expiration or cancellation as provided in the Plan or the Award Agreement. In another departure from prior guidelines, the new guideline recommends avoiding a repeat of the initial treatment regimen for a recurrence. Appropriate comparative data for these patients, however, are lacking. (r) Incentive Award means one or more Share Incentive Awards, collectively. Birch T, Golan Y, Rizzardini G, et al. A limited number of cost-effectiveness models have compared oral fidaxomicin 200 mg 2 times daily with oral vancomycin 125 mg 4 times daily for treatment of an initial CDI episode [2428]. Capital gain is disregarded . While the adjusted estimate for total CDI burden nationally decreased by 24% from the previous report, they still estimated 462 100 cases annually and the burden of first CDI recurrences was unchanged. (cc) Subsidiary means any subsidiary within the meaning of Rule405 under the Securities Act. Amcor Cares was founded as a principal tool in the United States to serve our communities. (b) Increase or Decrease in Issued Shares Without Consideration.